Aclaris Therapeutics Inc (NASDAQ: ACRS) kicked off on Tuesday, down -5.54% from the previous trading day, before settling in for the closing price of $3.07. Over the past 52 weeks, ACRS has traded in a range of $1.05-$3.47.
Annual sales at Healthcare sector company grew by 15.24% over the past five years. While this was happening, its average annual earnings per share was recorded 68.84%. With a float of $92.48 million, this company’s outstanding shares have now reached $108.34 million.
Let’s look at the performance matrix of the company that is accounted for 64 employees.
Aclaris Therapeutics Inc (ACRS) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Aclaris Therapeutics Inc is 14.64%, while institutional ownership is 67.26%.
Aclaris Therapeutics Inc (ACRS) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -1.01 earnings per share (EPS), lower than consensus estimate (set at -0.38) by -0.64. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.15 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 68.84% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 27.01% during the next five years compared to 15.24% growth over the previous five years of trading.
Aclaris Therapeutics Inc (NASDAQ: ACRS) Trading Performance Indicators
Take a look at Aclaris Therapeutics Inc’s (ACRS) current performance indicators. Last quarter, stock had a quick ratio of 3.92. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 19.96.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.38, a number that is poised to hit -0.15 in the next quarter and is forecasted to reach -0.60 in one year’s time.
Technical Analysis of Aclaris Therapeutics Inc (ACRS)
Aclaris Therapeutics Inc (NASDAQ: ACRS) saw its 5-day average volume 1.29 million, a positive change from its year-to-date volume of 1.06 million. As of the previous 9 days, the stock’s Stochastic %D was 17.33%.
During the past 100 days, Aclaris Therapeutics Inc’s (ACRS) raw stochastic average was set at 70.89%, which indicates a significant increase from 23.84% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.21 in the past 14 days, which was higher than the 0.16 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.60, while its 200-day Moving Average is $1.83. Nevertheless, the first resistance level for the watch stands at $3.05 in the near term. At $3.19, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.33. If the price goes on to break the first support level at $2.77, it is likely to go to the next support level at $2.63. Assuming the price breaks the second support level, the third support level stands at $2.49.
Aclaris Therapeutics Inc (NASDAQ: ACRS) Key Stats
The company with the Market Capitalisation of 314.20 million has total of 108,345K Shares Outstanding. Its annual sales at the moment are 18,720 K in contrast with the sum of -132,070 K annual income. Company’s last quarter sales were recorded 3,300 K and last quarter income was -14,610 K.
